GLP-1 and Depression: Evidence, FDA Review, and What to Watch
The question you’re asking
You know GLP-1 medications help with weight loss, but you’re wondering: what happens to your mood when you start? You may have read headlines about FDA warnings. Or maybe you struggle with depression and you’re trying to figure out whether GLP-1 is safe for you.
The answer is nuanced. The evidence shows that GLP-1 medications can improve mood for many patients, but not because they are treatments for depression. The mechanisms are more complex than that. And yes, the FDA reviewed reports of suicidal ideation, but they concluded there is no causal link. Here is what you need to know to make an informed decision with your provider.
How GLP-1 medications interact with the brain
GLP-1 (glucagon-like peptide-1) is not just a weight loss hormone. It is a signaling molecule that works throughout the body, including in the brain. GLP-1 receptors are found in several brain regions that regulate reward, mood, and emotional control, including the ventral tegmental area (involved in pleasure and motivation), the prefrontal cortex (involved in decision-making and emotional regulation), and the hippocampus (involved in memory and mood).
This is the biological foundation for the question: if GLP-1 acts on the brain, does it affect mood?
The short answer is, probably, but the effect is indirect and entangled with weight loss. That matters for how you interpret the clinical data.
What the clinical trials show
The SELECT trial and mood outcomes
The SELECT trial, published in the New England Journal of Medicine in 2023, followed 17,604 patients over approximately 5 years.[1] The trial’s primary focus was cardiovascular outcomes, but researchers also measured mental health using the PROMIS-29, a validated self-reported measure of psychological well-being, depression, anxiety, and social function.
The results: Patients taking semaglutide showed statistically significant improvements in mental health composite scores compared to placebo. Depression and anxiety scores improved. These improvements began early in the trial and were sustained over the 5-year period.[1]
Important context: These patients were not enrolled because they had depression. They were overweight or obese adults with existing cardiovascular disease or cardiovascular risk factors. The mood improvements were secondary observations. And crucially, patients in the semaglutide group were losing significant amounts of weight, which itself is known to improve depression and anxiety scores in most populations.
Separating medication-specific effects from weight loss effects is methodologically difficult. The researchers note that mood improvement may result from the direct neural action of semaglutide, from weight loss itself, or from both.
Real-world observational data
A 2024 analysis published in Nature Medicine examined the incidence of major depression and anxiety disorders in adults using GLP-1 receptor agonists compared to those using other weight loss medications or no medication.[2] The researchers found that GLP-1 users had lower incidence of depression and anxiety diagnosis during follow-up.
Again, critical context: This was observational data, not a randomized controlled trial. Patients choosing to use GLP-1 medications differ from other groups in ways that matter. Socioeconomic status, health literacy, access to care, and baseline depression risk all influence who gets prescribed what. The researchers were transparent about this limitation and cautious in their interpretation. The observed benefit could result from weight loss, from GLP-1’s direct brain effects, from unobserved patient characteristics, or from some combination of these.
The mechanisms behind mood improvement
If GLP-1 medications do improve mood, how?
Weight loss and body image
This is the largest and most direct mechanism. Obesity and depression are bidirectionally linked. People with obesity have higher rates of depression, and people with depression have higher rates of weight gain and obesity. Weight loss reduces depression and anxiety in most populations, independent of medication type.
When you lose weight on a GLP-1 medication, you gain several psychological benefits: improved energy and physical function, better sleep quality, increased confidence, reduced shame and stigma, improved self-image. These are not pharmacological effects. They are behavioral and psychological, but they are real and powerful.
For many patients, this is the primary source of mood improvement.
Reduced food obsession and mental burden
One of GLP-1’s effects is to quiet “food noise,” the constant mental urge to think about food, plan the next meal, or resist cravings. Many patients report that this reduction in food preoccupation frees up mental energy, reduces anxiety around eating, and improves mood. This is related to weight loss (because food noise typically decreases as you lose weight) but is distinct from it. The mental relief itself improves quality of life and mood.
Direct brain action
GLP-1 receptors in the brain do appear to have mood-relevant effects in animal models and small human studies. Semaglutide has been shown to reduce neuroinflammation in preclinical research.[3] Chronic neuroinflammation is implicated in the pathophysiology of major depression. If semaglutide reduces neuroinflammation in humans at clinically relevant doses, it could have a mood benefit independent of weight loss.
However, this is still early-stage research. It has not been formally tested in a randomized trial with depression as a primary outcome. The clinical significance of these findings remains unclear.
The FDA safety review: what you should know
In 2023, the FDA’s Office of Surveillance and Epidemiology reviewed reports submitted to the FDA Adverse Event Reporting System (FAERS) database related to suicidal ideation and behavior in patients taking GLP-1 receptor agonists. The review was triggered by increased media coverage and patient reports of suicidal thoughts.
The FDA’s conclusion, issued in January 2024: A causal relationship between GLP-1 receptor agonists and suicidal ideation has not been established.[4]
Here is what this means in plain language:
The FDA found that while suicidal ideation was reported in patients taking GLP-1 medications, the rate and pattern of reports did not demonstrate causation. The FAERS database captures all adverse events reported by patients, healthcare providers, and manufacturers. It does not prove that a drug caused an event. It identifies signals that warrant further investigation.
In this case, several factors complicate any causal inference:
Confounding by indication: Patients with obesity, metabolic syndrome, and type 2 diabetes have higher baseline rates of depression and suicidality than the general population. When you compare patients taking GLP-1 medications to the general population, you are not comparing equivalent groups.
Reporting bias: Media coverage of potential suicidality risks increases reporting of suicidal ideation among patients taking the medication, even if the risk has not changed. This is called stimulated reporting and is a known feature of the FAERS database.
Temporal association is not causation: The fact that a patient took GLP-1 and later experienced suicidal ideation does not mean the medication caused the ideation.
When the FDA controlled for these confounders and examined the data more carefully, the signal did not hold. The rate of suicidality in GLP-1 users was consistent with rates expected in the underlying population, not elevated.
The FDA did not add a suicidality warning to GLP-1 labels. Monitoring continues, but as of now, there is no established causal link between GLP-1 medications and suicidal ideation.[4]
Important: GLP-1 medications are not treatments for depression
To be clear: GLP-1 medications are not approved by the FDA for depression. They are not used in clinical practice to treat depression. Even if some patients experience mood improvement while taking GLP-1 for weight loss, that does not make GLP-1 a depression treatment.
If you have clinical depression that requires treatment, talk to your provider or a mental health professional about evidence-based treatments like antidepressant medications, therapy, or both. GLP-1 may be an additional tool that supports your overall health and mood, but it should not replace psychiatric treatment.
What you should tell your provider
Mental health screening is part of the intake process at Transformation Health and with most telehealth weight loss programs. Here is what your provider needs to know:
Current mental health status: Do you currently have depression, anxiety, bipolar disorder, or other mood disorders? Are you in treatment?
Psychiatric medication history: Are you taking any antidepressants, anti-anxiety medications, mood stabilizers, or other psychiatric medications?
Past suicidality: Have you ever experienced suicidal thoughts or attempted suicide? When? Are you at risk now?
Mental health treatment: Are you currently working with a therapist, counselor, psychiatrist, or other mental health provider?
Your provider uses this information to determine whether GLP-1 treatment is medically appropriate for you. Having a history of depression does not automatically disqualify you. But your provider needs to assess your current mental health status, your stability on any psychiatric medications, and your capacity to manage the behavioral demands of a GLP-1 program (dietary changes, medical appointments, self-monitoring).
What the research shows about mental health risk
You may have encountered conflicting headlines about GLP-1 medications and mental health. The data actually paints a more nuanced picture than the coverage suggests.
The SELECT trial, which enrolled patients with existing cardiovascular disease or risk factors (but not active psychiatric conditions), found significant improvements in mood and depression scores. A 2024 Nature Medicine analysis of real-world data in patients using GLP-1 medications also found lower rates of depression diagnosis.
However, a 2026 Swedish national cohort study published in The Lancet Psychiatry examined this question differently. The study followed 95,490 adults with a diagnosed history of depression, anxiety, or both over multiple years. The key finding: Semaglutide use was associated with a 42% decreased risk of worsening mental health, including psychiatric hospitalization, compared to periods when these patients were not taking GLP-1 medications. The same study found that semaglutide was associated with a 44% decreased risk of worsening depression and a 38% decreased risk of worsening anxiety.[5]
Why might these studies show different results? The SELECT trial excluded patients with active psychiatric conditions. The Swedish cohort explicitly included patients with diagnosed mental health disorders. This difference in study populations is important. It suggests that GLP-1 medications may actually be protective for people with a history of depression or anxiety, not harmful.
The practical implication for you: If you have a history of depression, anxiety, or another psychiatric condition, this is absolutely a conversation to have with your provider before starting GLP-1 treatment. These conditions are not necessarily a contraindication to treatment, but they warrant closer monitoring and clear communication about any mood changes during treatment. Your provider needs to know your baseline mental health status so they can assess whether treatment is appropriate and monitor you appropriately over time.
What mood changes to expect and monitor
Different patients experience different mood effects on GLP-1. This is normal and individual.
Positive mood changes (common):
- Improved mood and sense of well-being as weight loss progresses
- Increased energy and motivation
- Reduced anxiety related to food and eating
- Improved confidence and self-image
- Better sleep quality
Early transient mood effects (usually temporary):
- Temporary irritability or low mood in the first 1-2 weeks, often related to nausea or caloric deficit
- Mood typically stabilizes as nausea resolves and the body adjusts
When to contact your provider:
- Significant mood changes in either direction that persist beyond the first few weeks
- Persistent low mood, anhedonia (loss of pleasure), or hopelessness
- Increased anxiety that interferes with daily function
- Any thoughts of self-harm or suicide
Your provider wants to know about mood changes because they affect your safety and treatment plan. If you develop significant depression symptoms on GLP-1, that may warrant a dose adjustment, medication change, or additional mental health support. If you experience suicidal ideation, contact your provider immediately and seek mental health support.
When to Contact Your Provider About Mood Changes
Mild mood shifts in the first 1-2 weeks are common. Significant or persistent mood changes warrant contact with your provider. Reach out if you experience:
- Significant mood changes in either direction that persist beyond the first few weeks
- Persistent low mood or hopelessness lasting more than a few days
- Loss of interest or pleasure in activities you normally enjoy
- New or worsening anxiety that interferes with sleep or daily function
- Increased irritability or emotional sensitivity
Seek emergency care immediately if you experience:
- Thoughts of harming yourself
- Suicidal thoughts or urges
- Severe, uncontrollable emotional distress
Call 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.
The bigger picture: weight loss and mental health
Weight loss and mood are linked in complex ways. Losing weight usually improves mood and self-image, but it is not guaranteed, and it is not linear. Some patients feel better immediately. Others feel worse before they feel better, as they process changes in body image or face emotions they were previously numbing with food.
Your relationship with food, your body, and your identity matters. GLP-1 medications reduce the biological drive to eat, but they do not change your thoughts, beliefs, or emotional patterns around food and body. A comprehensive program that includes nutrition guidance, fitness support, and coaching addresses this broader context. Mental health support, whether through your program’s coaching or through a therapist, matters.
If you have a history of depression or disordered eating, tell your provider. There is no shame in this. Your provider needs the full picture to support you safely.
Getting started
Starting a GLP-1 program when you have depression or anxiety is possible, but it requires transparency and partnership with your provider. Here is what the intake process looks like:
Online assessment: You complete an intake form covering your full health history, including mental health history, medications, and any past suicidality.
Provider review: An independent, licensed provider reviews your information and assesses whether GLP-1 treatment is medically appropriate for you. Not all patients qualify.
Provider consultation: If appropriate, you may have a consultation (by phone or video) to discuss your health goals, answer questions, and clarify next steps.
Prescription (if appropriate): If your provider determines GLP-1 is appropriate, a prescription is written and sent to a licensed US compounding pharmacy.
Ongoing support: You receive medication, lab work, and coaching as part of your program. Any mood changes or concerns are addressed in follow-up appointments.
The program costs $249 to $339 per month depending on the medication, and includes medication, lab work, and coaching. There are no hidden fees. You can cancel anytime.
If you have a history of depression and you are considering GLP-1 treatment, this is a conversation worth having with your provider. The evidence suggests it may help. The safety data suggests it is unlikely to harm. Your individual circumstances and mental health stability matter most.
Citations
[1] Lincoff AM, Livingston Mackin C, Anderson G, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(21):1935-1946. https://pubmed.ncbi.nlm.nih.gov/37952131/
[2] Real-world observational data examining GLP-1 receptor agonist use and depression/anxiety outcomes. Nature Medicine. 2024. https://www.nature.com/articles/d41591-024-00041-y
[3] STEP 1 Trial: Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
[4] FDA. Evaluating the risk of suicidal thoughts or actions with incretin-mimetic drugs used to treat type 2 diabetes. FDA Safety Communication. January 2024. https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
[5] Swedish national cohort study on GLP-1 receptor agonists and mental health outcomes in adults with depression and anxiety. The Lancet Psychiatry. March 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00014-3/fulltext
Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. All prescriptions require evaluation by an independent, licensed healthcare provider. Not all patients will qualify. Results vary by individual. If you are experiencing significant mood changes or thoughts of self-harm, contact your provider and a mental health professional.